0001104659-24-009540.txt : 20240201 0001104659-24-009540.hdr.sgml : 20240201 20240201180155 ACCESSION NUMBER: 0001104659-24-009540 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240130 FILED AS OF DATE: 20240201 DATE AS OF CHANGE: 20240201 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Harris Matthew Scott CENTRAL INDEX KEY: 0001787762 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-32587 FILM NUMBER: 24588157 MAIL ADDRESS: STREET 1: C/O ALTIMMUNE, INC. STREET 2: 910 CLOPPER ROAD, SUITE 201S CITY: GAITHERSBURG STATE: MD ZIP: 20878 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Altimmune, Inc. CENTRAL INDEX KEY: 0001326190 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 202726770 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 910 CLOPPER ROAD STREET 2: SUITE 201S CITY: GAITHERSBURG STATE: MD ZIP: 20878 BUSINESS PHONE: 2406541450 MAIL ADDRESS: STREET 1: 910 CLOPPER ROAD STREET 2: SUITE 201S CITY: GAITHERSBURG STATE: MD ZIP: 20878 FORMER COMPANY: FORMER CONFORMED NAME: PHARMATHENE, INC DATE OF NAME CHANGE: 20071016 FORMER COMPANY: FORMER CONFORMED NAME: HEALTHCARE ACQUISITION CORP DATE OF NAME CHANGE: 20050505 4 1 tm244961-3_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2024-01-30 0 0001326190 Altimmune, Inc. ALT 0001787762 Harris Matthew Scott C/O ALTIMMUNE, INC., 910 CLOPPER ROAD, SUITE 201S GAITHERSBURG MD 20878 0 1 0 0 Chief Medical Officer 0 Common Stock, par value $0.0001 2024-01-30 4 M 0 9275 0 A 43277 D Common Stock, par value $0.0001 2024-01-30 4 F 0 2709 9.80 D 40568 D Common Stock, par value $0.0001 2024-01-31 4 A 0 3257 2.69 A 43825 D Restricted Stock Units 2024-01-30 4 M 0 9275 0.00 D Common Stock, par value $0.0001 9275 27825 D Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from August 1, 2023 through January 31, 2024. In accordance with the ESPP, these shares were purchased based on 85% of the opening price of the issuer's common stock on August 1, 2023. The RSUs become vested in substantially equal annual installments over the 4 years following January 30, 2023, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. /s/ Richard I. Eisenstadt, as Attorney-in-Fact 2024-02-01